Canopy Growth (CGC) Income towards Parent Company (2019 - 2025)
Canopy Growth (CGC) reported Income towards Parent Company of -$3.6 million for Q3 2025, down 251.5% on a YoY basis from $2.4 million in Q3 2024, and down 251.5% sequentially from $2.4 million in Q3 2024.
Canopy Growth (CGC) Income towards Parent Company (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Income towards Parent Company data on file, last reported at -$3.6 million in Q3 2025.
- For the quarter ending Q3 2025, Income towards Parent Company fell 251.5% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 193.02% YoY), and the FY2025 full-year result was -$55.2 million, changed N/A from the prior year.
- Income towards Parent Company retreated to -$3.6 million in Q3 2025, from $2.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $317.2 million in Q2 2021 to a low of -$1.6 billion in Q2 2022.
- A 5-year average of -$138.9 million and a median of -$25.5 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 442.79% in 2021 and sank 617.16% in 2022, its largest moves.
- Tracing CGC's Income towards Parent Company over 5 years: stood at -$91.6 million in 2021, then surged by 69.82% to -$27.6 million in 2022, then jumped by 135.81% to $9.9 million in 2023, then tumbled by 75.89% to $2.4 million in 2024, then sank by 251.5% to -$3.6 million in 2025.
- Business Quant data shows CGC's Income towards Parent Company at -$3.6 million in Q3 2025, $2.4 million in Q3 2024, and $1.5 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Canopy Growth | 276.52 Mn | 10.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.62 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 9.90 Mn |
| Sep 30, 2023 | -131.76 Mn |
| Jun 30, 2023 | -23.30 Mn |
| Mar 31, 2023 | -44.10 Mn |
| Dec 31, 2022 | -27.65 Mn |
| Sep 30, 2022 | -83.84 Mn |
| Jun 30, 2022 | -1.64 Bn |
| Mar 31, 2022 | -408.19 Mn |
| Dec 31, 2021 | -91.63 Mn |
| Sep 30, 2021 | -12.97 Mn |
| Jun 30, 2021 | 317.24 Mn |
| Mar 31, 2021 | -87.57 Mn |
| Dec 31, 2020 | -636.08 Mn |
| Sep 30, 2020 | -72.45 Mn |
| Jun 30, 2020 | -92.55 Mn |
| Mar 31, 2020 | -1.09 Bn |